AI-generated from publicly available materials.Novartis is revolutionizing chemical manufacturing controls (CMC) with a cutting-edge self-service platform developed in collaboration with Genedata, utilizing AI to enhance operational efficiency and reduce submission timelines.
The innovative platform, known internally as SPINE Explorer, facilitates real-time monitoring and in silico experimentation in drug manufacturing. Novartis's approach highlights the often-overlooked importance of CMC, which is crucial for ensuring drug quality and safety, and significantly impacts regulatory approvals. Notably, a large percentage of FDA response letters cite CMC-related deficiencies, underscoring its critical role in the drug development process.
Prior to integrating AI, Novartis faced challenges with vast amounts of unstructured data from scanned documents. The initial focus was on organizing this data semantically, transitioning from a document-centric to a data-centric framework. By leveraging Genedata Profiler, Novartis established a centralized system that supports data security and quality while enabling decentralized data ownership. This shift allowed for more effective data governance and collaboration among scientists.
Kalidindi's team has successfully integrated AI models to enhance data management and streamline workflows, enabling real-time insights and predictive analytics. The platform's capabilities extend to various use cases, including deviation detection in biologics manufacturing, which can significantly reduce batch failures and associated costs. As a result, Novartis anticipates substantial ROI and improved efficiency in its drug development processes, fostering a culture of data-driven decision-making among its scientists.